donepezil has been researched along with cefuroxime in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Bolognesi, ML; da Costa Nunes, JL; de Oliveira Miranda, C; de Oliveira, AS; Gandini, A; Gervasoni, S; Jung, M; Kobrlova, T; Massenzio, F; Monti, B; Petralla, S; Rossi, M; Senger, J; Simões Heyn Roth Cardoso, G; Soares Romeiro, LA; Soukup, O; Vistoli, G | 1 |
Benek, O; Benkova, M; Dolezal, R; Hepnarova, V; Hrabinova, M; Janockova, J; Jun, D; Kobrlova, T; Korabecny, J; Kucera, T; Mezeiova, E; Prchal, L; Sobolova, K; Soukup, O | 1 |
1 review(s) available for donepezil and cefuroxime
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for donepezil and cefuroxime
Article | Year |
---|---|
Novel Sustainable-by-Design HDAC Inhibitors for the Treatment of Alzheimer's Disease.
Topics: | 2019 |
Discovery of novel berberine derivatives with balanced cholinesterase and prolyl oligopeptidase inhibition profile.
Topics: Berberine; Blood-Brain Barrier; Cell Line, Tumor; Cholinesterase Inhibitors; Cholinesterases; Drug Design; Humans; Prolyl Oligopeptidases | 2020 |